Safety

VaxGen wins $80 million anthrax vaccine contract

Emergency Management Alert, October 8, 2003

Brisbane, CA-based biotechnology firm VaxGen won an $80.3 million federal contract on October 1 to continue development of a new genetically engineered anthrax vaccine, the Associated Press reports.

The three-year contract boosts VaxGen's chances of winning an even larger contract to manufacture the proposed $1.4 billion anthrax vaccine stockpile. The contract, awarded by the National Institute of Allergies and Infectious Diseases, funds animal and human experiments and lets the company manufacture three million doses of the vaccine.

VaxGen plans to test the vaccine's effectiveness on animals infected with anthrax; human volunteers will be injected with the experimental vaccine to determine its safety and whether it produces the desired immune response. The existing anthrax vaccine requires six shots over 18 months, plus an annual booster. VaxGen expects the new vaccine to require fewer shots.

    Hospital Safety Center
  • Hospital Safety Center

    Improve compliance with hospital safety standards from The Joint Commission, OSHA, and other regulators with this...

  • Healthcare Life Safety Compliance

    Learn Life Safety Code tips and interpretations for healthcare facilities with this in-depth monthly resource.

  • Hospital Safety Connection

    Stay on top of hospital safety requirements and best practices with our free, fast-paced weekly update.

  • Administering Your OSHA Program

    This course will help an employee new to the role of OSHA safety officer. It gives an overview of OSHA requirements and...

  • Medical OSHA Manual Combo

    Get into compliance with Quality America's OSHA Safety Program Manual and stay in compliance with OSHA Watch Newsletter...

Most Popular

Related Articles